Advertisement

Graves’ Disease: What Is the Role and Timing of Surgery?

  • Dawn M. Elfenbein
  • Rebecca S. SippelEmail author

Abstract

The surgical treatment of Graves’ disease classically was limited to a small subset of patients with contraindications to medical therapy or radioactive iodine or who presented with severe ophthalmopathy, complications of severe acute thyrotoxicosis, or concurrent thyroid nodules. With the introduction of endocrine surgery fellowship training and improving surgical outcomes, total thyroidectomy is now becoming more widely used as first-line therapy for Graves’ disease. This chapter will describe the evolving role of surgery for Graves’ disease, highlight circumstances where thyroidectomy is definitively the treatment of choice, and discuss controversies in the perioperative management of these patients.

Keywords

Graves’ disease Radioactive iodine ablation Thyroidectomy Quality of life Surgical decision-making Surgical volume outcomes 

References

  1. 1.
    Brent GA. Clinical practice. Graves’ disease. N Engl J Med. 2008;358(24):2594–605.CrossRefPubMedGoogle Scholar
  2. 2.
    Bahn RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, Klein I, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Endocr Pract. 2011;17(3):456–520.CrossRefPubMedGoogle Scholar
  3. 3.
    McGrogan A, Seaman HE, Wright JW, De Vries CS. The incidence of autoimmune thyroid disease: a systematic review of the literature. Clin Endocrinol. 2008;69(5):687–96.CrossRefGoogle Scholar
  4. 4.
    Ryodi E, Salmi J, Jaatinen P, Huhtala H, Saaristo R, Valimaki M, et al. Cardiovascular morbidity and mortality in surgically treated hyperthyroidism—a nation-wide cohort study with a long-term follow-up. Clin Endocrinol. 2014;80(5):743–50.CrossRefGoogle Scholar
  5. 5.
    Brandt F, Thvilum M, Almind D, Christensen K, Green A, Hegedus L, et al. Morbidity before and after the diagnosis of hyperthyroidism: a nationwide register-based study. PLoS One. 2013;8(6), e66711.PubMedCentralCrossRefPubMedGoogle Scholar
  6. 6.
    Brandt F, Thvilum M, Almind D, Christensen K, Green A, Hegedus L, et al. Hyperthyroidism and psychiatric morbidity: evidence from a Danish nationwide register study. Eur J Endocrinol. 2014;170(2):341–8.CrossRefPubMedGoogle Scholar
  7. 7.
    Hiromatsu Y, Eguchi H, Tani J, Kasaoka M, Teshima Y. Graves’ ophthalmopathy: epidemiology and natural history. Intern Med (Tokyo Japan). 2014;53(5):353–60.CrossRefGoogle Scholar
  8. 8.
    Torring O, Tallstedt L, Wallin G, Lundell G, Ljunggren JG, Taube A, et al. Graves’ hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine–a prospective, randomized study. Thyroid Study Group. J Clin Endocrinol Metabol. 1996;81(8):2986–93.Google Scholar
  9. 9.
    Burch HB, Burman KD, Cooper DS. A 2011 survey of clinical practice patterns in the management of Graves’ disease. J Clin Endocrinol Metab. 2012;97(12):4549–58.CrossRefPubMedGoogle Scholar
  10. 10.
    Liu J, Bargren A, Schaefer S, Chen H, Sippel RS. Total thyroidectomy: a safe and effective treatment for Graves’ disease. J Surg Res. 2011;168(1):1–4.PubMedCentralCrossRefPubMedGoogle Scholar
  11. 11.
    Welch KC, McHenry CR. Total thyroidectomy: is morbidity higher for Graves’ disease than nontoxic goiter? J Surg Res. 2011;170(1):96–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Yip J, Lang BH, Lo CY. Changing trend in surgical indication and management for Graves’ disease. Am J Surg. 2012;203(2):162–7.CrossRefPubMedGoogle Scholar
  13. 13.
    Genovese BM, Noureldine SI, Gleeson EM, Tufano RP, Kandil E. What is the best definitive treatment for Graves’ disease? A systematic review of the existing literature. Ann Surg Oncol. 2013;20(2):660–7.CrossRefPubMedGoogle Scholar
  14. 14.
    Snyder S, Govednik C, Lairmore T, Jiang DS, Song J. Total thyroidectomy as primary definitive treatment for Graves’ hyperthyroidism. Am Surg. 2013;79(12):1283–8.PubMedGoogle Scholar
  15. 15.
    Weetman AP. Grave’s disease 1835–2002. Horm Res. 2003;59 Suppl 1:114–8.CrossRefPubMedGoogle Scholar
  16. 16.
    Tomer Y, Huber A. The etiology of autoimmune thyroid disease: a story of genes and environment. J Autoimmun. 2009;32(3-4):231–9.PubMedCentralCrossRefPubMedGoogle Scholar
  17. 17.
    Sundaresh V, Brito JP, Wang Z, Prokop LJ, Stan MN, Murad MH, et al. Comparative effectiveness of therapies for Graves’ hyperthyroidism: a systematic review and network meta-analysis. J Clin Endocrinol Metabol. 2013;98(9):3671–7.CrossRefGoogle Scholar
  18. 18.
    Schussler-Fiorenza CM, Bruns CM, Chen H. The surgical management of Graves’ disease. J Surg Res. 2006;133(2):207–14.CrossRefPubMedGoogle Scholar
  19. 19.
    Institute of Medicine Committee on Quality of Health Care in A. Crossing the Quality Chasm: A New Health System for the 21st Century. Washington (DC): National Academies Press (US) Copyright 2001 by the National Academy of Sciences. All rights reserved.; 2001.Google Scholar
  20. 20.
    Rosenthal MS. Patient misconceptions and ethical challenges in radioactive iodine scanning and therapy. J Nucl Med Technol. 2006;34(3):143–50.PubMedGoogle Scholar
  21. 21.
    Calais PJ, Page AC, Turner JH. Management of fear of radiation exposure in carers of outpatients treated with iodine-131. Ann Nucl Med. 2012;26(6):508–14.CrossRefPubMedGoogle Scholar
  22. 22.
    Bahn RS, Burch HS, Cooper DS, Garber JR, Greenlee CM, Klein IL, et al. The role of propylthiouracil in the management of Graves’ disease in adults: report of a meeting jointly sponsored by the American Thyroid Association and the Food and Drug Administration. Thyroid. 2009;19(7):673–4.CrossRefPubMedGoogle Scholar
  23. 23.
    Glinoer D, Cooper DS. The propylthiouracil dilemma. Curr Opin Endocrinol Diabetes Obes. 2012;19(5):402–7.CrossRefPubMedGoogle Scholar
  24. 24.
    Wang TS. Endocrine surgery. Am J Surg. 2011;202(3):369–71.CrossRefPubMedGoogle Scholar
  25. 25.
    Kandil E, Noureldine SI, Abbas A, Tufano RP. The impact of surgical volume on patient outcomes following thyroid surgery. Surgery. 2013;154(6):1346–52. discussion 52–3.CrossRefPubMedGoogle Scholar
  26. 26.
  27. 27.
    Liu M, Jing D, Hu J, Yin S. Predictive factors of outcomes in personalized radioactive iodine (131I) treatment for Graves’ disease. Am J Med Sci. 2014;348:288–93.CrossRefPubMedGoogle Scholar
  28. 28.
    Alexander EK, Larsen PR. High dose of (131)I therapy for the treatment of hyperthyroidism caused by Graves’ disease. J Clin Endocrinol Metab. 2002;87(3):1073–7.PubMedGoogle Scholar
  29. 29.
    Schneider DF, Sonderman PE, Jones MF, Ojomo KA, Chen H, Jaume JC, et al. Failure of radioactive Iodine in the treatment of hyperthyroidism. Ann Surg Oncol. 2014;21(13):4174–80.PubMedCentralCrossRefPubMedGoogle Scholar
  30. 30.
    Ross DS. Radioiodine therapy for hyperthyroidism. N Engl J Med. 2011;364(6):542–50.CrossRefPubMedGoogle Scholar
  31. 31.
    Sisson JC, Freitas J, McDougall IR, Dauer LT, Hurley JR, Brierley JD, et al. Radiation safety in the treatment of patients with thyroid diseases by radioiodine 131I: practice recommendations of the American Thyroid Association. Thyroid. 2011;21(4):335–46.CrossRefPubMedGoogle Scholar
  32. 32.
    Metso S, Auvinen A, Huhtala H, Salmi J, Oksala H, Jaatinen P. Increased cancer incidence after radioiodine treatment for hyperthyroidism. Cancer. 2007;109(10):1972–9.CrossRefPubMedGoogle Scholar
  33. 33.
    Metso S, Auvinen A, Salmi J, Huhtala H, Jaatinen P. Increased long-term cardiovascular morbidity among patients treated with radioactive iodine for hyperthyroidism. Clin Endocrinol. 2008;68(3):450–7.Google Scholar
  34. 34.
    Ponto KA, Zang S, Kahaly GJ. The tale of radioiodine and Graves’ orbitopathy. Thyroid. 2010;20(7):785–93.CrossRefPubMedGoogle Scholar
  35. 35.
    Metso S, Jaatinen P, Huhtala H, Luukkaala T, Oksala H, Salmi J. Long-term follow-up study of radioiodine treatment of hyperthyroidism. Clin Endocrinol. 2004;61(5):641–8.CrossRefGoogle Scholar
  36. 36.
    Aydogan F, Ayhan Tuzcu E, Aydogan A, Akkucuk S, Coskun M, Ustun I, et al. Effect of radioactive iodine therapy on lacrimal gland functions in patients with hyperthyroidism. Clin Nucl Med. 2014;39(4):315–8.CrossRefPubMedGoogle Scholar
  37. 37.
    Wilhelm SM, McHenry CR. Total thyroidectomy is superior to subtotal thyroidectomy for management of Graves’ disease in the United States. World J Surg. 2010;34(6):1261–4.CrossRefPubMedGoogle Scholar
  38. 38.
    Ku CF, Lo CY, Chan WF, Kung AW, Lam KS. Total thyroidectomy replaces subtotal thyroidectomy as the preferred surgical treatment for Graves’ disease. ANZ J Surg. 2005;75(7):528–31.CrossRefPubMedGoogle Scholar
  39. 39.
    Stalberg P, Svensson A, Hessman O, Akerstrom G, Hellman P. Surgical treatment of Graves’ disease: evidence-based approach. World J Surg. 2008;32(7):1269–77.CrossRefPubMedGoogle Scholar
  40. 40.
    Feroci F, Rettori M, Borrelli A, Coppola A, Castagnoli A, Perigli G, et al. A systematic review and meta-analysis of total thyroidectomy versus bilateral subtotal thyroidectomy for Graves’ disease. Surgery. 2014;155(3):529–40.CrossRefPubMedGoogle Scholar
  41. 41.
    Guo Z, Yu P, Liu Z, Si Y, Jin M. Total thyroidectomy vs bilateral subtotal thyroidectomy in patients with Graves’ diseases: a meta-analysis of randomized clinical trials. Clin Endocrinol. 2013;79(5):739–46.Google Scholar
  42. 42.
    Oltmann SC, Brekke AV, Schneider DF, Schaefer SC, Chen H, Sippel RS. Preventing postoperative hypocalcemia in patients with Graves disease: a prospective study. Ann Surg Oncol. 2015;22(3):95208.CrossRefGoogle Scholar
  43. 43.
    Mok VM, Oltmann SC, Chen H, Sippel RS, Schneider DF. Identifying predictors of a difficult thyroidectomy. J Surg Res. 2014;190(1):157–63.PubMedCentralCrossRefPubMedGoogle Scholar
  44. 44.
    Shin JJ, Milas M, Mitchell J, Berber E, Gutnick J, Siperstein A. The endocrine surgery job market: a survey of fellows, department chairs, and surgery recruiters. J Surg Educ. 2013;70(3):377–83.CrossRefPubMedGoogle Scholar
  45. 45.
    Sahin M, Guvener ND, Ozer F, Sengul A, Ertugrul D, Tutuncu NB. Thyroid cancer in hyperthyroidism: incidence rates and value of ultrasound-guided fine-needle aspiration biopsy in this patient group. J Endocrinol Investig. 2005;28(9):815–8.CrossRefGoogle Scholar
  46. 46.
    Cibas ES, Ali SZ. The Bethesda system for reporting thyroid cytopathology. Thyroid. 2009;19(11):1159–65.CrossRefPubMedGoogle Scholar
  47. 47.
    Laurberg P, Wallin G, Tallstedt L, Abraham-Nordling M, Lundell G, Tørring O. TSH-receptor autoimmunity in Graves’ disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study. Eur J Endocrinol. 2008;158(1):69–75.CrossRefPubMedGoogle Scholar
  48. 48.
    Nor Azlin MI, Bakin YD, Mustafa N, Wahab NA, Johari MJ, Kamarudin NA, et al. Thyroid autoantibodies and associated complications during pregnancy. J Obstet Gynaecol. 2010;30(7):675–8.CrossRefPubMedGoogle Scholar
  49. 49.
    Peroni E, Angiolini MR, Vigone MC, Mari G, Chiumello G, Beretta E, et al. Surgical management of pediatric Graves’ disease: an effective definitive treatment. Pediatr Surg Int. 2012;28(6):609–14.CrossRefPubMedGoogle Scholar
  50. 50.
    Rivkees SA. Pediatric Graves’ disease: controversies in management. Horm Res Paediatr. 2010;74(5):305–11.CrossRefPubMedGoogle Scholar
  51. 51.
    Ljunggren JG, Torring O, Wallin G, Taube A, Tallstedt L, Hamberger B, et al. Quality of life aspects and costs in treatment of Graves’ hyperthyroidism with antithyroid drugs, surgery, or radioiodine: results from a prospective, randomized study. Thyroid. 1998;8(8):653–9.CrossRefPubMedGoogle Scholar
  52. 52.
    In H, Pearce EN, Wong AK, Burgess JF, McAneny DB, Rosen JE. Treatment options for Graves disease: a cost-effectiveness analysis. J Am Coll Surg. 2009;209(2):170–9. e1–2.CrossRefPubMedGoogle Scholar
  53. 53.
    Hughes OR, Scott-Coombes DM. Hypocalcaemia following thyroidectomy for treatment of Graves’ disease: implications for patient management and cost-effectiveness. J Laryngol Otol. 2011;125(8):849–52.CrossRefPubMedGoogle Scholar
  54. 54.
    Grodski S, Stalberg P, Robinson BG, Delbridge LW. Surgery versus radioiodine therapy as definitive management for graves’ disease: the role of patient preference. Thyroid. 2007;17(2):157–60.CrossRefPubMedGoogle Scholar
  55. 55.
    Watt T, Hegedus L, Groenvold M, Bjorner JB, Rasmussen AK, Bonnema SJ, et al. Validity and reliability of the novel thyroid-specific quality of life questionnaire, ThyPRO. Eur J Endocrinol. 2010;162(1):161–7.CrossRefPubMedGoogle Scholar
  56. 56.
    Bukvic B, Zivaljevic V, Sipetic S, Diklic A, Tausanovic K, Stojanovic D, et al. Improved quality of life in hyperthyroidism patients after surgery. J Surg Res. 2015;193(2):724–30.CrossRefPubMedGoogle Scholar
  57. 57.
    Jin J, Sandoval V, Lawless ME, Sehgal AR, McHenry CR. Disparity in the management of Graves’ disease observed at an urban county hospital: a decade-long experience. Am J Surg. 2012;204(2):199–202.PubMedCentralCrossRefPubMedGoogle Scholar
  58. 58.
    Elfenbein DM, Schneider DF, Havelna J, Chen H, Sippel RS. Clinical and socioeconomic factors influence treatment decisions in Graves’ disease. Ann Surg Oncol. 2015;22(4):1196–9.61.PubMedCentralCrossRefPubMedGoogle Scholar
  59. 59.
    Shinall Jr MC, Broome JT, Baker A, Solorzano CC. Is potassium iodide solution necessary before total thyroidectomy for Graves disease? Ann Surg Oncol. 2013;20(9):2964–7.CrossRefPubMedGoogle Scholar
  60. 60.
    Akamizu T, Satoh T, Isozaki O, Suzuki A, Wakino S, Iburi T, et al. Diagnostic criteria and clinico-epidemiological features of thyroid storm based on a nationwide survey. Thyroid. 2012;22(7):661–79.PubMedCentralCrossRefPubMedGoogle Scholar
  61. 61.
    Shinall Jr MC, Broome JT, Nookala R, Shinall JB, Kiernan C, Parks 3rd L, et al. Total thyroidectomy for Graves’ disease: compliance with American Thyroid Association guidelines may not always be necessary. Surgery. 2013;154(5):1009–15.PubMedCentralCrossRefPubMedGoogle Scholar
  62. 62.
    Langley RW, Burch HB. Perioperative management of the thyrotoxic patient. Endocrinol Metab Clin N Am. 2003;32(2):519–34.CrossRefGoogle Scholar
  63. 63.
    Annerbo M, Hultin H, Stalberg P, Hellman P. Left-shifted relation between calcium and parathyroid hormone in Graves’ disease. J Clin Endocrinol Metab. 2014;99(2):545–51.CrossRefPubMedGoogle Scholar
  64. 64.
    Sanabria A, Ramirez A, Kowalski LP, Silver CE, Shaha AR, Owen RP, et al. Neuromonitoring in thyroidectomy: a meta-analysis of effectiveness from randomized controlled trials. European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS): affiliated with the German Society for Oto-Rhino-Laryngology. Head Neck Surg. 2013;270(8):2175–89.Google Scholar
  65. 65.
    Dralle H, Sekulla C, Lorenz K, Brauckhoff M, Machens A. Intraoperative monitoring of the recurrent laryngeal nerve in thyroid surgery. World J Surg. 2008;32(7):1358–66.CrossRefPubMedGoogle Scholar
  66. 66.
    Rulli F, Ambrogi V, Dionigi G, Amirhassankhani S, Mineo TC, Ottaviani F, et al. Meta-analysis of recurrent laryngeal nerve injury in thyroid surgery with or without intraoperative nerve monitoring. Acta Otorhinolaryngol Ital. 2014;34(4):223–9.PubMedCentralPubMedGoogle Scholar
  67. 67.
    Sitges-Serra A, Fontane J, Duenas JP, Duque CS, Lorente L, Trillo L, et al. Prospective study on loss of signal on the first side during neuromonitoring of the recurrent laryngeal nerve in total thyroidectomy. Br J Surg. 2013;100(5):662–6.CrossRefPubMedGoogle Scholar
  68. 68.
    Schneider R, Randolph GW, Sekulla C, Phelan E, Thanh PN, Bucher M, et al. Continuous intraoperative vagus nerve stimulation for identification of imminent recurrent laryngeal nerve injury. Head Neck. 2013;35(11):1591–8.CrossRefPubMedGoogle Scholar
  69. 69.
    Ojomo KA, Schneider DF, Reiher AE, Lai N, Schaefer S, Chen H, et al. Using body mass index to predict optimal thyroid dosing after thyroidectomy. J Am Coll Surg. 2013;216(3):454–60.PubMedCentralCrossRefPubMedGoogle Scholar
  70. 70.
    Watanabe N, Narimatsu H, Noh JY, Yamaguchi T, Kobayashi K, Kami M, et al. Antithyroid drug-induced hematopoietic damage: a retrospective cohort study of agranulocytosis and pancytopenia involving 50,385 patients with Graves’ disease. J Clin Endocrinol Metab. 2012;97(1):E49–53.CrossRefPubMedGoogle Scholar
  71. 71.
    Metso S, Jaatinen P, Huhtala H, Auvinen A, Oksala H, Salmi J. Increased cardiovascular and cancer mortality after radioiodine treatment for hyperthyroidism. J Clin Endocrinol Metab. 2007;92(6):2190–6.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.Department of SurgeryUniversity of WisconsinMadisonUSA
  2. 2.Section of Endocrine Surgery, Department of SurgeryUniversity of WisconsinMadisonUSA

Personalised recommendations